YPEL1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09263(YPEL1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P09263(YPEL1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

YPEL1 (Yippee-like 1) is a member of the YPEL gene family, evolutionarily conserved proteins implicated in cellular senescence, cell cycle regulation, and tumor suppression. The YPEL1 gene encodes a 15 kDa nuclear protein that interacts with chromatin and modulates transcriptional activity. Studies suggest YPEL1 induces cell cycle arrest by downregulating cyclin-dependent kinases (CDKs) and upregulating p21. linking it to senescence pathways. Its expression is frequently downregulated in cancers, including breast, lung, and colorectal carcinomas, correlating with poor prognosis, metastasis, and epithelial-mesenchymal transition (EMT).

YPEL1 antibodies are essential tools for investigating its biological roles, detecting protein localization (e.g., nuclear/cytoplasmic shifts during stress), and quantifying expression in clinical samples. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercially available antibodies often target specific epitopes, such as the N-terminal region (e.g., Rabbit monoclonal clones). Validation includes testing in knockdown/knockout models to confirm specificity.

Research using YPEL1 antibodies has highlighted its dual role: as a tumor suppressor in some contexts and a potential oncogenic driver in others, depending on cellular microenvironment and post-translational modifications. Recent studies also explore its utility as a prognostic biomarker. However, antibody cross-reactivity with other YPEL family members (e.g., YPEL2-5) remains a technical challenge, necessitating careful experimental controls.